文献速递围术期管理与 ERAS急腹症与外科感染

外科医生应了解的NOAC围术期管理要点

What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants: A Review.
PubMed 文献 · JAMA Surg · 2018-01-01

NOAC效果可预测但常规难以检测,围术期最佳停药与重启时机尚缺乏高质量证据。

要点

  • 机械瓣或肌酐清除率<15 mL/min者不推荐使用NOAC。
  • 肾功能正常者术前停药48至72小时,残留抗凝作用极小或无。
  • 达比加群已有逆转剂,阿哌沙班、依度沙班和利伐沙班逆转剂尚在审评。

核心结论

  • NOAC抗凝效果可预测但常规临床实践难以检测,围术期使用仍存在诸多不确定性。

主要发现

  • NOAC不推荐用于机械心脏瓣膜或晚期肾病(肌酐清除率<15 mL/min)患者。
  • 肾功能正常者术前停用NOAC 48至72小时,残留抗凝作用极小或无。
  • 达比加群已有临床可用的逆转剂,阿哌沙班、依度沙班和利伐沙班的逆转剂尚在监管审评中。
  • NOAC抗凝效果的实验室检测非常规可用。
  • 围术期NOAC最佳停药和重启时机的高质量数据缺乏,尤其在高出血风险手术患者中。

关键数值与推荐

  • NOAC不推荐用于机械心脏瓣膜或肌酐清除率<15 mL/min的患者。
  • 肾功能正常时,术前停用NOAC 48至72小时残留抗凝作用极小或无。

临床怎么用

  • 术前应评估肾功能以确定NOAC停药时机,肾功能正常者提前48至72小时停药。
  • 机械瓣或肌酐清除率<15 mL/min者应避免使用NOAC。
  • 需紧急干预的NOAC治疗患者,达比加群可用逆转剂,其他NOAC逆转剂尚在审评。

局限性

  • 围术期NOAC最佳停药和重启时机的高质量数据缺乏,尤其在高出血风险手术患者中。
  • NOAC抗凝效果的实验室检测非常规可用,常规临床难以测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Non-vitamin K oral anticoagulants (NOACs) are increasingly prescribed for patients to treat or prevent arterial or venous thromboembolism. The following 4 NOAC agents are approved by the US Food and Drug Administration for clinical use: dabigatran etexilate, apixaban, edoxaban tosylate, and rivaroxaban. A good understanding of these agents' pharmacologic properties is important for surgeons given their marked differences compared with warfarin sodium. This review highlights key practical issues surrounding the use of NOACs in the perioperative setting. OBSERVATIONS: The PubMed and Cochrane Library databases were searched for English-language studies from May 1, 2009, until May 1, 2017, for randomized clinical trials, meta-analyses, systematic reviews, observational studies, and clinical guidelines. From a systematic review of the published literature that included 70 articles and 166 404 patients, this study identified 5 key practical issues surrounding the use of NOACs in the perioperative setting. These include patient populations for which NOAC use is indicated and contraindicated, the timing of NOAC treatment cessation before invasive interventions, management of NOAC-treated patients requiring urgent interventions, the need for "bridging," and the timing of NOAC treatment's reinitiation after invasive interventions. Important findings are as follows: NOAC agents are not recommended for patients with mechanical heart valves or advanced kidney disease (creatinine clearance, <15 mL/min); minimal to no anticoagulant effect remains when therapy with a NOAC is withheld for 48 to 72 hours before surgery in the context of normal kidney function; a reversal agent is clinically available for dabigatran, while reversal agents for apixaban, edoxaban, and rivaroxaban are under regulatory review; and laboratory testing of the anticoagulant effects of NOACs are not routinely available. There is a paucity of high-quality data on the optimal timing of NOAC cessation and resumption in the perioperative period, particularly for patients who undergo procedures with high bleeding risk. CONCLUSIONS AND RELEVANCE: The anticoagulant effect of NOAC agents is predictable but not readily measurable in routine clinical practice. A number of uncertainties remain surrounding the use of these agents in the perioperative setting. Ongoing prospective studies and randomized clinical trials will provide greater clarity on these management issues in the near future.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Verma A, Ha ACT, Rutka JT, et al. What Surgeons Should Know About Non-Vitamin K Oral Anticoagulants: A Review. JAMA Surg. 2018. PMID: 29710221. doi:10.1001/jamasurg.2018.0374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。